Explore Stanford technologies available for licensing:

Disease indication -Acute asthma, COPD, other bronchoconstrictive disorders (bronchial asthma, allergic asthma, intrinsic asthma, airway hyper-responsiveness, chronic bronchitis) with potential for treating heart failure.

Researchers at Stanford University and Washington University in St. Louis have discovered a novel molecular pathway for the treatment of opioid overdose.

Researchers at Stanford have synthesized a potential novel class of pain relief drugs.

Disease Indication: Pain relief

Drug Format: Small molecule

Drug Class: First in class

Research Stage: In vitro/Lead selection

Target: CB1R

Adrenergic receptors are plasma membrane proteins that mediate cellular responses to the hormone/neurotransmitters adrenaline and nonadrenaline which are released from sympathetic nerve terminals or the adrenal gland.

Adrenergic receptors are plasma membrane proteins that mediate cellular responses to the hormone/neurotransmitters adrenaline and nonadrenaline which are released from sympathetic nerve terminals or the adrenal gland.

Adrenergic receptors are plasma membrane proteins that mediate cellular responses to the hormone/neurotransmitters adrenaline and nonadrenaline which are released from sympathetic nerve terminals or the adrenal gland.

S97-236- Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)
S97-237- Alpha 2b Adrenergic Receptor Gene Disruption Mouse (A2bARGDM)
S97-238- Alpha 2c Adrenergic Receptor Gene Disruption Mouse (A2cARGDM)

S97-236- Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)
S97-237- Alpha 2b Adrenergic Receptor Gene Disruption Mouse (A2bARGDM)
S97-238- Alpha 2c Adrenergic Receptor Gene Disruption Mouse (A2cARGDM)